 New Life Therapeutics NLT to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories Upfront and potential milestone payments totaling up to 21 Million with up to 30 royalties on commercial sales NLT to fund Phase 1b2a clinical trial and submit an IND planned for the second half of 2021 PRINCETON, NJ ACCESSWIRE May 3, 2021 Sonnet BioTherapeutics Holdings, Inc. NASDAQ:SONN Sonnet or the Company, a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has executed a definitive agreement with New Life Therapeutics Pte. Ltd. NLT of Singapore for the license of low-dose Interleukin 6, or IL-6, for the treatment of Diabetic Peripheral Neuropathy DPN. 